Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 18 | 2023 | 222 | 1.790 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 2021 | 46 | 1.190 |
Why?
|
| Lymphoma, Non-Hodgkin | 7 | 2017 | 33 | 1.050 |
Why?
|
| Arabinonucleosides | 4 | 2021 | 6 | 0.980 |
Why?
|
| Lymphoma | 3 | 2023 | 30 | 0.970 |
Why?
|
| Antibodies, Monoclonal | 8 | 2011 | 185 | 0.960 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2023 | 7 | 0.960 |
Why?
|
| Rituximab | 15 | 2023 | 45 | 0.910 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2019 | 32 | 0.860 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 169 | 0.750 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 10 | 2017 | 25 | 0.740 |
Why?
|
| Adenine Nucleotides | 2 | 2010 | 2 | 0.690 |
Why?
|
| Burkitt Lymphoma | 3 | 2021 | 7 | 0.560 |
Why?
|
| Paraproteinemias | 2 | 2019 | 6 | 0.540 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2015 | 5 | 0.490 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2015 | 52 | 0.470 |
Why?
|
| Adult | 20 | 2021 | 7336 | 0.440 |
Why?
|
| Middle Aged | 22 | 2023 | 8403 | 0.430 |
Why?
|
| Aged | 21 | 2023 | 8501 | 0.430 |
Why?
|
| Treatment Outcome | 16 | 2021 | 3231 | 0.420 |
Why?
|
| Humans | 37 | 2023 | 25692 | 0.400 |
Why?
|
| Necrobiotic Xanthogranuloma | 1 | 2011 | 2 | 0.380 |
Why?
|
| Plasma Cells | 1 | 2011 | 6 | 0.380 |
Why?
|
| Mediastinum | 1 | 2011 | 7 | 0.380 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2011 | 2 | 0.380 |
Why?
|
| Male | 22 | 2022 | 13917 | 0.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 14 | 0.360 |
Why?
|
| Cyclophosphamide | 8 | 2021 | 43 | 0.360 |
Why?
|
| Cranial Irradiation | 2 | 2007 | 13 | 0.340 |
Why?
|
| Doxorubicin | 6 | 2021 | 47 | 0.330 |
Why?
|
| Female | 22 | 2021 | 14273 | 0.310 |
Why?
|
| Vincristine | 6 | 2019 | 17 | 0.300 |
Why?
|
| Aged, 80 and over | 10 | 2023 | 4459 | 0.300 |
Why?
|
| Disease-Free Survival | 7 | 2021 | 152 | 0.300 |
Why?
|
| Prednisone | 6 | 2019 | 58 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2021 | 157 | 0.290 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2007 | 1 | 0.280 |
Why?
|
| Arsenicals | 1 | 2007 | 7 | 0.280 |
Why?
|
| Oxides | 1 | 2007 | 13 | 0.280 |
Why?
|
| Sarcoma, Myeloid | 1 | 2007 | 4 | 0.280 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2023 | 12 | 0.280 |
Why?
|
| Ear Neoplasms | 1 | 2007 | 7 | 0.280 |
Why?
|
| Brain Neoplasms | 2 | 2006 | 76 | 0.270 |
Why?
|
| Recurrence | 6 | 2020 | 275 | 0.270 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 11 | 0.270 |
Why?
|
| HIV Infections | 2 | 2021 | 457 | 0.260 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2006 | 10 | 0.260 |
Why?
|
| Drug Administration Schedule | 6 | 2019 | 152 | 0.260 |
Why?
|
| Biomarkers | 3 | 2019 | 554 | 0.240 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 281 | 0.240 |
Why?
|
| Immunotherapy | 2 | 2008 | 53 | 0.230 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2003 | 2 | 0.220 |
Why?
|
| Lymphoma, B-Cell | 3 | 2008 | 8 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2021 | 14 | 0.210 |
Why?
|
| Prognosis | 5 | 2021 | 739 | 0.200 |
Why?
|
| Remission Induction | 6 | 2015 | 80 | 0.200 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2011 | 16 | 0.190 |
Why?
|
| Deubiquitinating Enzymes | 1 | 2020 | 1 | 0.170 |
Why?
|
| Benzylidene Compounds | 1 | 2020 | 1 | 0.170 |
Why?
|
| Azepines | 1 | 2020 | 3 | 0.170 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 18 | 0.170 |
Why?
|
| Young Adult | 4 | 2021 | 1855 | 0.160 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 7 | 0.160 |
Why?
|
| Phthalazines | 1 | 2019 | 6 | 0.160 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 44 | 0.160 |
Why?
|
| Central Nervous System | 3 | 2023 | 51 | 0.160 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 332 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 18 | 0.160 |
Why?
|
| Piperazines | 1 | 2019 | 75 | 0.150 |
Why?
|
| Neutropenia | 4 | 2012 | 14 | 0.150 |
Why?
|
| Cytosine | 2 | 2021 | 5 | 0.150 |
Why?
|
| Retrospective Studies | 4 | 2023 | 3220 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 198 | 0.150 |
Why?
|
| Medical Oncology | 1 | 2018 | 35 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2019 | 98 | 0.150 |
Why?
|
| Cardiology | 1 | 2018 | 52 | 0.140 |
Why?
|
| Cachexia | 1 | 2017 | 11 | 0.140 |
Why?
|
| Immunity | 1 | 2017 | 15 | 0.140 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2016 | 8 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 39 | 0.140 |
Why?
|
| Stroke Volume | 1 | 2016 | 49 | 0.140 |
Why?
|
| Biopsy | 2 | 2019 | 199 | 0.130 |
Why?
|
| Registries | 1 | 2017 | 170 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2019 | 207 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 57 | 0.130 |
Why?
|
| Induction Chemotherapy | 1 | 2015 | 12 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 18 | 0.120 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 60 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 2 | 2023 | 7 | 0.110 |
Why?
|
| Leukopenia | 2 | 2011 | 5 | 0.110 |
Why?
|
| Lymphoma, Follicular | 2 | 2011 | 4 | 0.110 |
Why?
|
| Methotrexate | 2 | 2023 | 34 | 0.110 |
Why?
|
| Cytarabine | 3 | 2023 | 11 | 0.100 |
Why?
|
| Daunorubicin | 2 | 2015 | 5 | 0.100 |
Why?
|
| Transcriptome | 1 | 2012 | 74 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 177 | 0.100 |
Why?
|
| Obesity | 1 | 2014 | 290 | 0.100 |
Why?
|
| Agranulocytosis | 1 | 2011 | 3 | 0.090 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2011 | 6 | 0.090 |
Why?
|
| Yttrium Radioisotopes | 1 | 2011 | 10 | 0.090 |
Why?
|
| Cytokines | 1 | 2012 | 212 | 0.090 |
Why?
|
| Retreatment | 1 | 2010 | 7 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2010 | 36 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2011 | 392 | 0.080 |
Why?
|
| Platelet Count | 2 | 2007 | 14 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2020 | 49 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 698 | 0.070 |
Why?
|
| Tretinoin | 1 | 2007 | 13 | 0.070 |
Why?
|
| Injections, Spinal | 1 | 2007 | 30 | 0.070 |
Why?
|
| Vascular Neoplasms | 1 | 2006 | 4 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1689 | 0.070 |
Why?
|
| ADAMTS13 Protein | 1 | 2006 | 5 | 0.070 |
Why?
|
| Plasma Exchange | 1 | 2006 | 11 | 0.060 |
Why?
|
| ADAM Proteins | 1 | 2006 | 39 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2006 | 72 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2006 | 71 | 0.060 |
Why?
|
| Radiography | 1 | 2007 | 574 | 0.060 |
Why?
|
| Twins, Dizygotic | 1 | 2005 | 3 | 0.060 |
Why?
|
| United States | 2 | 2021 | 1943 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 120 | 0.060 |
Why?
|
| Etoposide | 2 | 2019 | 25 | 0.060 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 1 | 0.060 |
Why?
|
| Antigens, CD20 | 1 | 2003 | 4 | 0.060 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2003 | 5 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2003 | 21 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 37 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2003 | 5 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 12 | 0.050 |
Why?
|
| K562 Cells | 1 | 2003 | 3 | 0.050 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2003 | 29 | 0.050 |
Why?
|
| Telomerase | 1 | 2003 | 9 | 0.050 |
Why?
|
| Histones | 1 | 2003 | 27 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2003 | 158 | 0.050 |
Why?
|
| Apoptosis | 1 | 2003 | 177 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2003 | 155 | 0.050 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 1 | 0.050 |
Why?
|
| Voriconazole | 1 | 2022 | 12 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 124 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2022 | 40 | 0.050 |
Why?
|
| Azacitidine | 1 | 2021 | 9 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 249 | 0.050 |
Why?
|
| United Kingdom | 1 | 2021 | 52 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2021 | 6 | 0.050 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 10 | 0.050 |
Why?
|
| Incidence | 1 | 2023 | 731 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2006 | 827 | 0.040 |
Why?
|
| Thrombocytopenia | 2 | 2012 | 20 | 0.040 |
Why?
|
| Folic Acid | 1 | 2019 | 21 | 0.040 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 2 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 560 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 21 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 1 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2019 | 4 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 13 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 13 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 17 | 0.040 |
Why?
|
| Anemia | 2 | 2012 | 88 | 0.040 |
Why?
|
| Vidarabine | 2 | 2011 | 8 | 0.040 |
Why?
|
| Risk Factors | 1 | 2005 | 2224 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 1084 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 509 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 62 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 20 | 0.040 |
Why?
|
| Cardiologists | 1 | 2018 | 8 | 0.040 |
Why?
|
| Mitoxantrone | 2 | 2011 | 4 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 97 | 0.040 |
Why?
|
| Bortezomib | 1 | 2017 | 2 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 2 | 2006 | 9 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2015 | 1633 | 0.030 |
Why?
|
| Disease Progression | 2 | 2012 | 664 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 105 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 201 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 1781 | 0.030 |
Why?
|
| Adolescent | 1 | 2021 | 2076 | 0.030 |
Why?
|
| Naphthalimides | 1 | 2015 | 1 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2015 | 1 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 2 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 913 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 472 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 36 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2014 | 49 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2012 | 4 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2012 | 103 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2014 | 410 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2003 | 284 | 0.030 |
Why?
|
| Pneumonia | 1 | 2012 | 60 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 1336 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 48 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 246 | 0.020 |
Why?
|
| Nausea | 1 | 2007 | 22 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2007 | 13 | 0.020 |
Why?
|
| Creatinine | 1 | 2007 | 47 | 0.020 |
Why?
|
| Cisplatin | 1 | 2007 | 49 | 0.020 |
Why?
|
| Animals | 1 | 2014 | 3510 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2006 | 51 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 325 | 0.020 |
Why?
|
| Teniposide | 1 | 2004 | 1 | 0.010 |
Why?
|
| Bleomycin | 1 | 2004 | 2 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2004 | 30 | 0.010 |
Why?
|
| Patient Selection | 1 | 2005 | 170 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 315 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2004 | 151 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 2003 | 3 | 0.010 |
Why?
|
| S Phase | 1 | 2003 | 10 | 0.010 |
Why?
|
| E2F1 Transcription Factor | 1 | 2003 | 5 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 10 | 0.010 |
Why?
|
| Karyotyping | 1 | 2003 | 8 | 0.010 |
Why?
|
| Granulocytes | 1 | 2003 | 14 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 46 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 32 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2003 | 47 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 73 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 123 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 140 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 100 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 111 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2003 | 79 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 187 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 341 | 0.010 |
Why?
|